Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSQP7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating competitive capability in unrestricted federal procurement. The delivery order was issued under the company's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support recurring medical supply needs of military healthcare facilities worldwide.
This award represents one of numerous delivery orders DMS Pharmaceutical Group has received from the Defense Logistics Agency since winning the PPV-G GEN V prime vendor contract on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. XOLAIR, a biologic immunosuppressant used for allergic and asthma-related conditions, falls within the company's established product portfolio of branded and generic pharmaceuticals, biologics, and medical consumables. The delivery order positions DMS Pharmaceutical Group as a critical pharmaceutical supplier supporting Department of Defense healthcare operations globally, leveraging its established performance and small business status within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FSQP7?
SPE2DR26FSQP7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FSQP7 worth?
The government has obligated $15,792 on SPE2DR26FSQP7.
Is contract SPE2DR26FSQP7 an order under another contract?
Yes. SPE2DR26FSQP7 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQP7 competed?
The extent of competition for SPE2DR26FSQP7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award